These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 2554499)

  • 1. Potentiation by heparin fragment CY 222 (Choay) of thrombolysis induced by human tissue-type plasminogen activator.
    Juhan-Vague I; Stassen JM; Alessi MC; Elias A; Aillaud MF; Serradimigni A; Collen D
    Semin Thromb Hemost; 1989 Oct; 15(4):390-4. PubMed ID: 2554499
    [No Abstract]   [Full Text] [Related]  

  • 2. Potentiation by heparin fragments of thrombolysis induced with human tissue-type plasminogen activator or human single-chain urokinase-type plasminogen activator.
    Stassen JM; Juhan-Vague I; Alessi MC; De Cock F; Collen D
    Thromb Haemost; 1987 Oct; 58(3):947-50. PubMed ID: 2829381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect.
    Gurewich V; Pannell R
    Thromb Haemost; 1987 Jun; 57(3):372-3. PubMed ID: 3116707
    [No Abstract]   [Full Text] [Related]  

  • 4. [Combined thrombolysis by pharmacokinetically different plasminogen activators].
    Maksimenko AV
    Bioorg Khim; 1998 May; 24(5):376-80. PubMed ID: 9661792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laboratory control of heparin and heparin fragment treatment: an experimental study.
    Doutremepuich C; Lalanne MC; Guyot M; Doutremepuich F; De Sèze O; Toulemonde F
    Semin Thromb Hemost; 1989 Oct; 15(4):373-7. PubMed ID: 2554497
    [No Abstract]   [Full Text] [Related]  

  • 6. [Low molecular weight heparin CY 222 (Choay) potentiates the thrombolytic effect of 1-PA in rabbits with experimental thrombosis of the jugular vein].
    Juhan-Vague I; Stassen JM; Alessi MC; de Cock F; Serradimigni A; Collen D
    J Mal Vasc; 1987; 12 Suppl B():64-5. PubMed ID: 2834493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.
    Collen D
    Prog Hemost Thromb; 1986; 8():1-18. PubMed ID: 3104986
    [No Abstract]   [Full Text] [Related]  

  • 8. The nature of synergy between tissue-type and single chain urokinase-type plasminogen activators.
    Fry ET; Mack DL; Sobel BE
    Thromb Haemost; 1989 Nov; 62(3):909-16. PubMed ID: 2512679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Thrombolysis using tissue-type plasminogen activator and pro-urokinase: synergism; mutants and hybrids].
    Páramo JA; Fernández FJ; Cuesta B; Paloma MJ; Rocha E
    Sangre (Barc); 1989 Aug; 34(4):297-9. PubMed ID: 2505395
    [No Abstract]   [Full Text] [Related]  

  • 10. Strategy for the development of the low molecular weight heparin fraction CY 216 in the prevention of postoperative deep vein thromboses in general surgery.
    Toulemonde F
    Semin Thromb Hemost; 1989 Oct; 15(4):395-400. PubMed ID: 2554500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrinolytic agents.
    Schmitz-Huebner U; van de Loo J
    Clin Haematol; 1981 Jun; 10(2):481-96. PubMed ID: 7032785
    [No Abstract]   [Full Text] [Related]  

  • 12. The contribution of anti-Xa and anti-IIa activities to the profibrinolytic activity of low-molecular-weight heparins.
    Ammollo CT; Semeraro F; Semeraro N; Colucci M
    Thromb Haemost; 2009 Apr; 101(4):782-5. PubMed ID: 19350129
    [No Abstract]   [Full Text] [Related]  

  • 13. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.
    Collen D; Stassen JM; De Cock F
    Thromb Haemost; 1987 Oct; 58(3):943-6. PubMed ID: 3124288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-chain urokinase-type plasminogen activator: mechanism of action and thrombolytic properties.
    Lijnen HR; Stump DC; Collen DC
    Semin Thromb Hemost; 1987 Apr; 13(2):152-9. PubMed ID: 3114883
    [No Abstract]   [Full Text] [Related]  

  • 15. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator.
    Watahiki Y; Scully MF; Ellis V; Kakkar VV
    Thromb Haemost; 1989 Jun; 61(3):502-6. PubMed ID: 2508259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of standard heparin and a low molecular weight heparin on thrombolytic and fibrinolytic activity of single-chain urokinase plasminogen activator in vitro.
    Lourenço DM; Dosne AM; Kher A; Samama M
    Thromb Haemost; 1989 Nov; 62(3):923-6. PubMed ID: 2556812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Thrombolytics and their use].
    Alessi MC; Juhan-Vague I
    Rev Prat; 1999 Oct; 49(15):1654-8. PubMed ID: 10581996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--III. Thrombolytic properties of natural and recombinant urokinase in rabbits with experimental jugular vein thrombosis.
    Collen D; Stassen JM; Blaber M; Winkler M; Verstraete M
    Thromb Haemost; 1984 Aug; 52(1):27-30. PubMed ID: 6541817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tissue plasminogen activator].
    Matsuo O
    Rinsho Ketsueki; 1984 Jul; 25(7):1004-10. PubMed ID: 6542154
    [No Abstract]   [Full Text] [Related]  

  • 20. Synergism of thrombolytic agents: investigational procedures and clinical potential.
    Collen D
    Circulation; 1988 Apr; 77(4):731-5. PubMed ID: 3127075
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.